Adam Keeney's most recent trade in Biogen Inc was a trade of 8,025 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 8,025 | 8,025 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 3,278 | 6,875 (0%) | 0% | 0 | Common Stock | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 3,278 | 6,557 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,802 | 4,186 (0%) | 0% | 0 | Common Stock | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,802 | 1,802 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 994 | 5,881 (0%) | 0% | 201.2 | 199,973 | Common Stock |
| Biogen | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 589 | 3,597 (0%) | 0% | 201.2 | 118,495 | Common Stock |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 938 | 939 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 938 | 2,838 (0%) | 0% | 0 | Common Stock | |
| Biogen | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.93 per share. | 01 May 2025 | 454 | 2,384 (0%) | 0% | 120.9 | 54,902 | Common Stock |
| Biogen | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 9,835 | 9,835 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,801 | 3,604 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,801 | 2,463 (0%) | 0% | 0 | Common Stock | |
| Biogen | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 563 | 1,900 (0%) | 0% | 141.3 | 79,580 | Common Stock |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 938 | 1,877 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 938 | 938 (0%) | 0% | 0 | Common Stock | |
| Biogen | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.13 per share. | 01 May 2024 | 276 | 662 (0%) | 0% | 216.1 | 59,652 | Common Stock |
| Biogen | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 5,405 | 5,405 | - | - | Restricted Stock Unit | |
| Biogen | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 2,815 | 2,815 | - | - | Restricted Stock Unit |